室管膜肿瘤:近期世界卫生组织组织病理学与遗传学更新及其影像特征概述
2021年世界卫生组织中枢神经系统肿瘤分类(CNS5)按解剖位置和基因组标志将室管膜瘤分为10个亚组,幕上肿瘤由ZFTA或YAP1融合定义,后颅窝分为PFA和PFB组,脊髓室管膜瘤由MYCN扩增定义。本文综述各亚组的影像特征及最新靶向分子治疗。
要点
- 幕上ZFTA融合室管膜瘤好发于大脑皮层、以囊性成分为主,沿硬脑膜瓣复发倾向较高。
- 幕上YAP1-MAMLD1融合室管膜瘤位于脑室内或室旁、多结节实性为主,预后显著优于ZFTA融合者。
- PFA为儿童旁中线侵袭性肿块、常钙化,起源于第四脑室顶外侧部,预后、复发及转移率均劣于PFB。
核心结论
- CNS5分类按解剖位置和基因组标志将室管膜瘤分为10个亚组,影像表现虽有显著重叠,但神经放射科医生需熟悉该分类以理解肿瘤行为,例如ZFTA融合阳性室管膜瘤沿硬脑膜瓣复发的倾向较高。
研究设计与样本
- 综述,阐述CNS5室管膜瘤分子分类、各亚组影像特征并简要概述最新靶向分子治疗。
关键影像表现/征象
- 幕上ZFTA融合室管膜瘤优先位于大脑皮层,以囊性成分为主。
- YAP1-MAMLD1融合室管膜瘤位于脑室内或室旁,以显著多结节实性成分为主。
- PFA室管膜瘤为旁中线肿块、常伴钙化,见于幼儿,起源于第四脑室顶外侧部。
- PFB室管膜瘤通常位于中线、无钙化的实性-囊性肿块,见于青少年和年轻成人,起源于第四脑室底。
- 室管膜下瘤为非侵袭性、脑室内、缓慢生长的良性肿瘤,预后极佳。
诊断标准与关键数值
- 幕上肿瘤由ZFTA融合(原RELA)或YAP1融合定义。
- 后颅窝肿瘤分为A组(PFA)和B组(PFB)。
- 脊髓室管膜瘤由MYCN扩增定义。
- 室管膜下瘤可见于上述所有解剖腔室。
- 若无致病性基因融合或分子诊断不可行,则归入「未在其他地方分类」或「未特指」的开放类别。
临床应用与阅片要点
- 神经放射科医生需熟悉CNS5分类以理解肿瘤行为,例如ZFTA融合阳性室管膜瘤沿硬脑膜瓣复发的倾向较高。
- YAP1-MAMLD1融合室管膜瘤预后显著优于ZFTA融合者。
- PFA较PFB预后更差、复发率更高、转移率更高。
- 黏液乳头型脊髓室管膜瘤因复发率高现被视为2级。
- 脊髓MYCN室管膜瘤为侵袭性肿瘤,常伴柔脑膜播散、复发且预后差。
局限性
- 目前分子分类尚未增进对室管膜下瘤和黏液乳头型类别的临床病理理解,但鉴于分子进展,未来可能会改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The 2021 World Health Organization Classification of Tumors of the Central Nervous System (CNS5), introduced significant changes, impacting tumors ranging from glial to ependymal neoplasms. Ependymal tumors were previously classified and graded based on histopathology, which had limited clinical and prognostic utility. The updated CNS5 classification now divides ependymomas into 10 subgroups based on anatomic location (supratentorial, posterior fossa, and spinal compartment) and genomic markers. Supratentorial tumors are defined by zinc finger translocation associated (ZFTA) (formerly v-rel avian reticuloendotheliosis viral oncogene [RELA]), or yes-associated protein 1 (YAP1) fusion; posterior fossa tumors are classified into groups A (PFA) and B (PFB), spinal ependymomas are defined by MYCN amplification. Subependymomas are present across all these anatomic compartments. The new classification kept an open category of "not elsewhere classified" or "not otherwise specified" if no pathogenic gene fusion is identified or if the molecular diagnosis is not feasible. Although there is significant overlap in the imaging findings of these tumors, a neuroradiologist needs to be familiar with updated CNS5 classification to understand tumor behavior, for example, the higher tendency for tumor recurrence along the dural flap for ZFTA fusion-positive ependymomas. On imaging, supratentorial ZFTA-fused ependymomas are preferentially located in the cerebral cortex, carrying predominant cystic components. YAP1-MAMLD1-fused ependymomas are intra- or periventricular with prominent multinodular solid components and have significantly better prognosis than ZFTA-fused counterparts. PFA ependymomas are aggressive paramedian masses with frequent calcification, seen in young children, originating from the lateral part of the fourth ventricular roof. PFB ependymomas are usually midline, noncalcified solid-cystic masses seen in adolescents and young adults arising from the fourth ventricular floor. PFA has a poorer prognosis, higher recurrence, and higher metastatic rate than PFB. Myxopapillary spinal ependymomas are now considered grade II due to high recurrence rates. Spinal-MYCN ependymomas are aggressive tumors with frequent leptomeningeal spread, relapse, and poor prognosis. Subependymomas are noninvasive, intraventricular, slow-growing benign tumors with an excellent prognosis. Currently, the molecular classification does not enhance the clinicopathologic understanding of subependymoma and myxopapillary categories. However, given the molecular advancements, this will likely change in the future. This review provides an updated molecular classification of ependymoma, discusses the individual imaging characteristics, and briefly outlines the latest targeted molecular therapies.
引用
- Soni N, Ora M, Bathla G, et al. Ependymal Tumors: Overview of the Recent World Health Organization Histopathologic and Genetic Updates with an Imaging Characteristic. AJNR Am J Neuroradiol. 2024. PMID: 38844368. doi:10.3174/ajnr.A8237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。